Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Obesity | Original investigation

High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study

Authors: Hyun-Jung Lee, Eue-Keun Choi, Kyung-Do Han, Da Hye Kim, Euijae Lee, So-Ryoung Lee, Seil Oh, Gregory Y. H. Lip

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Bodyweight variability is a risk factor for atrial fibrillation (AF). We aimed to examine the relationship between bodyweight variability and the risk of AF in patients with type 2 diabetes mellitus (DM), and whether this relationship was affected by baseline body mass index (BMI), weight change, or advanced diabetic stage.

Methods

A nationwide population-based cohort of 670,797 patients with type 2 DM from the Korean National Health Insurance Service database without a history of AF and with ≥ 3 measurements of bodyweight over a 5-year period were followed up for AF development. Intra-individual bodyweight variability was calculated using variability independent of mean, and high bodyweight variability was defined as the quintile with the highest variability with the lower four quintiles as reference.

Results

During a median of 7.0 years of follow-up, 22,019 patients (3.3%) newly developed AF. After multivariate adjustment, those in the highest quintile of bodyweight variability showed a higher risk of incident AF (HR 1.16, 95% CI 1.12–1.20) compared to those in the lower 4 quintiles with reference bodyweight variability, irrespective of baseline BMI group and direction of overall weight change. This association was greater in magnitude in subjects with lower BMI, those on insulin, and those with a DM duration of greater than 5 years. In sensitivity analyses, high bodyweight variability was consistently associated with AF development using other indices of variability and adjusting for glycemic variability.

Conclusions

High variability in bodyweight was associated with AF development, independently of traditional cardiovascular risk factors and baseline BMI. This association was stronger in underweight patients and with advanced diabetic stage. Weight fluctuation may interfere with the beneficial effects of weight loss and should be avoided when possible in weight control regimens for DM patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.PubMedCrossRef Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.PubMedCrossRef
3.
go back to reference Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501–17.PubMedPubMedCentralCrossRef Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501–17.PubMedPubMedCentralCrossRef
4.
go back to reference Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, Lee KN, Shim J, Kim JS, Kim YH. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.PubMedPubMedCentralCrossRef Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, Lee KN, Shim J, Kim JS, Kim YH. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.PubMedPubMedCentralCrossRef
5.
go back to reference Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Ostgren CJ, Sundstrom J. Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol. 2015;14:5.PubMedPubMedCentralCrossRef Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Ostgren CJ, Sundstrom J. Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol. 2015;14:5.PubMedPubMedCentralCrossRef
6.
go back to reference Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol. 2016;68(23):2497–504.PubMedPubMedCentralCrossRef Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K. Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol. 2016;68(23):2497–504.PubMedPubMedCentralCrossRef
7.
go back to reference Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050–60.PubMedCrossRef Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050–60.PubMedCrossRef
8.
go back to reference Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–69.PubMedCrossRef Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–69.PubMedCrossRef
9.
go back to reference American Diabetes A. 8. obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S89–97.CrossRef American Diabetes A. 8. obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S89–97.CrossRef
10.
go back to reference Mackie GM, Samocha-Bonet D, Tam CS. Does weight cycling promote obesity and metabolic risk factors? Obes Res Clin Pract. 2017;11(2):131–9.PubMedCrossRef Mackie GM, Samocha-Bonet D, Tam CS. Does weight cycling promote obesity and metabolic risk factors? Obes Res Clin Pract. 2017;11(2):131–9.PubMedCrossRef
11.
go back to reference Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, Lee SH. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018;138(23):2627–37.PubMedCrossRef Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, Lee SH. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. Circulation. 2018;138(23):2627–37.PubMedCrossRef
12.
go back to reference Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376(14):1332–40.PubMedCrossRef Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376(14):1332–40.PubMedCrossRef
13.
go back to reference Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body weight variability and cardiovascular outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004724.PubMedCrossRef Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body weight variability and cardiovascular outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Qual Outcomes. 2018;11(11):e004724.PubMedCrossRef
14.
go back to reference Yeboah P, Hsu FC, Bertoni AG, Yeboah J. Body mass index, change in weight, body weight variability and outcomes in type 2 diabetes mellitus (from the ACCORD Trial). Am J Cardiol. 2019;123(4):576–81.PubMedCrossRef Yeboah P, Hsu FC, Bertoni AG, Yeboah J. Body mass index, change in weight, body weight variability and outcomes in type 2 diabetes mellitus (from the ACCORD Trial). Am J Cardiol. 2019;123(4):576–81.PubMedCrossRef
15.
go back to reference Lee HJ, Choi EK, Han KD, Lee E, Moon I, Lee SR, Cha MJ, Oh S, Lip GYH. Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. Heart Rhythm. 2019;17:365–71.PubMedCrossRef Lee HJ, Choi EK, Han KD, Lee E, Moon I, Lee SR, Cha MJ, Oh S, Lip GYH. Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. Heart Rhythm. 2019;17:365–71.PubMedCrossRef
16.
go back to reference Lee HJ, Lee SR, Choi EK, Han KD, Oh S. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc. 2019;8(23):e012771.PubMedPubMedCentral Lee HJ, Lee SR, Choi EK, Han KD, Oh S. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc. 2019;8(23):e012771.PubMedPubMedCentral
17.
go back to reference Noh J, Han KD, Ko SH, Ko KS, Park CY. Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep. 2017;7:46656.PubMedPubMedCentralCrossRef Noh J, Han KD, Ko SH, Ko KS, Park CY. Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep. 2017;7:46656.PubMedPubMedCentralCrossRef
18.
go back to reference Kim MK, Han K, Koh ES, Kim ES, Lee MK, Nam GE, Kwon HS. Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol. 2019;18(1):36.PubMedPubMedCentralCrossRef Kim MK, Han K, Koh ES, Kim ES, Lee MK, Nam GE, Kwon HS. Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol. 2019;18(1):36.PubMedPubMedCentralCrossRef
19.
go back to reference Lee H, Choi EK, Lee SH, Han KD, Rhee TM, Park CS, Lee SR, Choe WS, Lim WH, Kang SH, et al. Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study. Int J Cardiol. 2017;240:221–7.PubMedCrossRef Lee H, Choi EK, Lee SH, Han KD, Rhee TM, Park CS, Lee SR, Choe WS, Lim WH, Kang SH, et al. Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study. Int J Cardiol. 2017;240:221–7.PubMedCrossRef
20.
go back to reference Lee HJ, Choi EK, Lee SH, Kim YJ, Han KD, Oh S. Risk of ischemic stroke in metabolically healthy obesity: a nationwide population-based study. PLoS ONE. 2018;13(3):e0195210.PubMedPubMedCentralCrossRef Lee HJ, Choi EK, Lee SH, Kim YJ, Han KD, Oh S. Risk of ischemic stroke in metabolically healthy obesity: a nationwide population-based study. PLoS ONE. 2018;13(3):e0195210.PubMedPubMedCentralCrossRef
21.
go back to reference Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019;73(25):3295–308.PubMedCrossRef Lee SR, Lee HJ, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Direct oral anticoagulants in patients with atrial fibrillation and liver disease. J Am Coll Cardiol. 2019;73(25):3295–308.PubMedCrossRef
22.
go back to reference Yano Y. Visit-to-Visit blood pressure variability-what is the current challenge? Am J Hypertens. 2017;30(2):112–4.PubMedCrossRef Yano Y. Visit-to-Visit blood pressure variability-what is the current challenge? Am J Hypertens. 2017;30(2):112–4.PubMedCrossRef
23.
go back to reference WHO Western Pacific Region IIAftSoO, International Obesity TaskForce: The Asia-Pacific perspective: Redefining obesity and its treatment. 2000. WHO Western Pacific Region IIAftSoO, International Obesity TaskForce: The Asia-Pacific perspective: Redefining obesity and its treatment. 2000.
24.
go back to reference Serban C, Arinze JT, Starreveld R, Lanters EAH, Yaksh A, Kik C, Acardag Y, Knops P, Bogers A, de Groot NMS. The impact of obesity on early postoperative atrial fibrillation burden. J Thorac Cardiovasc Surg. 2020;159(3):930–8.PubMedCrossRef Serban C, Arinze JT, Starreveld R, Lanters EAH, Yaksh A, Kik C, Acardag Y, Knops P, Bogers A, de Groot NMS. The impact of obesity on early postoperative atrial fibrillation burden. J Thorac Cardiovasc Surg. 2020;159(3):930–8.PubMedCrossRef
25.
go back to reference Lynch KT, Mehaffey JH, Hawkins RB, Hassinger TE, Hallowell PT, Kirby JL. Bariatric surgery reduces incidence of atrial fibrillation: a propensity score-matched analysis. Surg Obes Relat Dis. 2019;15(2):279–85.PubMedCrossRef Lynch KT, Mehaffey JH, Hawkins RB, Hassinger TE, Hallowell PT, Kirby JL. Bariatric surgery reduces incidence of atrial fibrillation: a propensity score-matched analysis. Surg Obes Relat Dis. 2019;15(2):279–85.PubMedCrossRef
26.
go back to reference Aldaas OM, Lupercio F, Han FT, Hoffmayer KS, Krummen D, Ho G, Raissi F, Birgersdotter-Green U, Feld GK, Hsu JC. Meta-analysis of effect of modest (>/=10%) weight loss in management of overweight and obese patients with atrial fibrillation. Am J Cardiol. 2019;124(10):1568–74.PubMedCrossRefPubMedCentral Aldaas OM, Lupercio F, Han FT, Hoffmayer KS, Krummen D, Ho G, Raissi F, Birgersdotter-Green U, Feld GK, Hsu JC. Meta-analysis of effect of modest (>/=10%) weight loss in management of overweight and obese patients with atrial fibrillation. Am J Cardiol. 2019;124(10):1568–74.PubMedCrossRefPubMedCentral
27.
go back to reference Strohacker K, Carpenter KC, McFarlin BK. Consequences of weight cycling: an increase in disease risk? Int J Exerc Sci. 2009;2(3):191–201.PubMedPubMedCentral Strohacker K, Carpenter KC, McFarlin BK. Consequences of weight cycling: an increase in disease risk? Int J Exerc Sci. 2009;2(3):191–201.PubMedPubMedCentral
28.
go back to reference Feng T, Vegard M, Strand LB, Laugsand LE, Morkedal B, Aune D, Vatten L, Ellekjaer H, Loennechen JP, Mukamal K, et al. Weight and weight change and risk of atrial fibrillation: the HUNT study. Eur Heart J. 2019;40(34):2859–66.PubMedCrossRef Feng T, Vegard M, Strand LB, Laugsand LE, Morkedal B, Aune D, Vatten L, Ellekjaer H, Loennechen JP, Mukamal K, et al. Weight and weight change and risk of atrial fibrillation: the HUNT study. Eur Heart J. 2019;40(34):2859–66.PubMedCrossRef
29.
go back to reference Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2014;7(4):620–5.PubMedPubMedCentralCrossRef Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2014;7(4):620–5.PubMedPubMedCentralCrossRef
30.
go back to reference Kang SH, Choi EK, Han KD, Lee SR, Lim WH, Cha MJ, Cho Y, Oh IY, Oh S. Underweight is a risk factor for atrial fibrillation: a nationwide population-based study. Int J Cardiol. 2016;215:449–56.PubMedCrossRef Kang SH, Choi EK, Han KD, Lee SR, Lim WH, Cha MJ, Cho Y, Oh IY, Oh S. Underweight is a risk factor for atrial fibrillation: a nationwide population-based study. Int J Cardiol. 2016;215:449–56.PubMedCrossRef
31.
go back to reference Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, Siscovick DS, Tracy RP, Heckbert SR, Psaty BM, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart. 2015;101(17):1368–74.PubMedCrossRef Macheret F, Bartz TM, Djousse L, Ix JH, Mukamal KJ, Zieman SJ, Siscovick DS, Tracy RP, Heckbert SR, Psaty BM, et al. Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults. Heart. 2015;101(17):1368–74.PubMedCrossRef
32.
go back to reference Anaszewicz M, Banas W, Wawrzenczyk A, Budzynski J. Body composition in patients with atrial fibrillation. Acta Cardiol Sin. 2019;35(5):484–92.PubMedPubMedCentral Anaszewicz M, Banas W, Wawrzenczyk A, Budzynski J. Body composition in patients with atrial fibrillation. Acta Cardiol Sin. 2019;35(5):484–92.PubMedPubMedCentral
33.
go back to reference Yan YQ, Zou LJ. Relation between zinc, copper, and magnesium concentrations following cardiopulmonary bypass and postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Biol Trace Elem Res. 2012;148(2):148–53.PubMedCrossRef Yan YQ, Zou LJ. Relation between zinc, copper, and magnesium concentrations following cardiopulmonary bypass and postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Biol Trace Elem Res. 2012;148(2):148–53.PubMedCrossRef
34.
go back to reference Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.PubMedPubMedCentralCrossRef Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019;18(1):121.PubMedPubMedCentralCrossRef
35.
go back to reference Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107–15.PubMedCrossRef Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107–15.PubMedCrossRef
36.
go back to reference Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, Kuo CT, Yeh YH. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.PubMedPubMedCentralCrossRef Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, Kuo CT, Yeh YH. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18(1):125.PubMedPubMedCentralCrossRef
37.
go back to reference Mahajan R, Nelson A, Pathak RK, Middeldorp ME, Wong CX, Twomey DJ, Carbone A, Teo K, Agbaedeng T, Linz D, et al. Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat. JACC Clin Electrophysiol. 2018;4(12):1529–40.PubMedCrossRef Mahajan R, Nelson A, Pathak RK, Middeldorp ME, Wong CX, Twomey DJ, Carbone A, Teo K, Agbaedeng T, Linz D, et al. Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat. JACC Clin Electrophysiol. 2018;4(12):1529–40.PubMedCrossRef
38.
go back to reference Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4(8):436–43.PubMedCrossRef Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4(8):436–43.PubMedCrossRef
39.
go back to reference Agbaedeng T, Twomey D, Thanigaimani S, Linz D, Lau D, Mahajan R, Sanders P. Weight fluctuation induces formation of pro-arrhythmic substrate by fibro-fatty depositions and residual electro-structural remodelling: evidence from an ovine model. Heart Lung Circ. 2019;28:s148.CrossRef Agbaedeng T, Twomey D, Thanigaimani S, Linz D, Lau D, Mahajan R, Sanders P. Weight fluctuation induces formation of pro-arrhythmic substrate by fibro-fatty depositions and residual electro-structural remodelling: evidence from an ovine model. Heart Lung Circ. 2019;28:s148.CrossRef
40.
go back to reference Simonds SE, Pryor JT, Cowley MA. Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. Physiol Behav. 2018;194:184–90.PubMedCrossRef Simonds SE, Pryor JT, Cowley MA. Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. Physiol Behav. 2018;194:184–90.PubMedCrossRef
41.
go back to reference Rhee EJ, Cho JH, Kwon H, Park SE, Park CY, Oh KW, Park SW, Lee WY. Increased risk of diabetes development in individuals with weight cycling over 4 years: the Kangbuk Samsung Health study. Diabetes Res Clin Pract. 2018;139:230–8.PubMedCrossRef Rhee EJ, Cho JH, Kwon H, Park SE, Park CY, Oh KW, Park SW, Lee WY. Increased risk of diabetes development in individuals with weight cycling over 4 years: the Kangbuk Samsung Health study. Diabetes Res Clin Pract. 2018;139:230–8.PubMedCrossRef
42.
go back to reference Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7.PubMedCrossRef Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7.PubMedCrossRef
43.
go back to reference Saito S, Teshima Y, Fukui A, Kondo H, Nishio S, Nakagawa M, Saikawa T, Takahashi N. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res. 2014;104(1):5–14.PubMedCrossRef Saito S, Teshima Y, Fukui A, Kondo H, Nishio S, Nakagawa M, Saikawa T, Takahashi N. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res. 2014;104(1):5–14.PubMedCrossRef
44.
go back to reference Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. Anatol J Cardiol. 2017;18(6):410–6.PubMedPubMedCentral Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. Anatol J Cardiol. 2017;18(6):410–6.PubMedPubMedCentral
45.
go back to reference Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRef Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRef
Metadata
Title
High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study
Authors
Hyun-Jung Lee
Eue-Keun Choi
Kyung-Do Han
Da Hye Kim
Euijae Lee
So-Ryoung Lee
Seil Oh
Gregory Y. H. Lip
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01059-8

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine